NCT04297410 (NALuPROST) is a NA clinical trial of 177Lu-PSMA-I&T Radionuclide in Prostate Cancer, sponsored by Rabin Medical Center.

Who is sponsoring NCT04297410?

NCT04297410 is sponsored by Rabin Medical Center.

What drugs are being tested in NCT04297410?

Interventions in NCT04297410: 177Lu-PSMA-I&T Radionuclide.

What condition does NCT04297410 study?

NCT04297410 studies Prostate Cancer.

Is NCT04297410 still recruiting?

NCT04297410 is currently status unknown. Last updated 5 March 2020.

Last reviewed 2020-03-05 · How we verify

NCT04297410: NALuPROST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

177Lu-PSMA-I&T Prior to Radical Prostatectomy for Locally Advanced Disease

Status unknown NA Last updated 5 March 2020

What this trial tests

NA trial testing 177Lu-PSMA-I&T Radionuclide in Prostate Cancer in 5 participants. Status unknown.

Timeline

20 November 2019

Primary endpoint
20 November 2021

20 April 2022

Quick facts

Lead sponsor	Rabin Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	20 November 2019
Primary completion	20 November 2021
Estimated completion	20 April 2022
Sites	1 location across Israel

Drugs / interventions tested

177Lu-PSMA-I&T Radionuclide

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Rabin Medical Center

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Despite surgical advances, up to 50% of patients with high-risk locally advanced prostate cancer will die from their disease. Drug therapy before surgery has the potential to improve treatment success by lowering tumor volume in the prostate and treating small metastases. PET PSMA is an advanced imaging technique that allows the identification of areas involved by the tumor in the prostate or in the pelvis. This technique is based on the protein PSMA (prostate-specific membrane antigen) which is located on the tumor cells. The presence of PSMA on tumor cells has been recently used for treatment purposes. A chemical element (Lutetium) that binds to PSMA and emits local radiation can destroy tumors cells. This treatment has been used in patients with advanced metastatic disease and showed promising results. The investigators hypothesized that using these particles can improve long term results in patients who undergo surgery for prostate cancer which has not extensively spread. The investigators will assess both the immediate and long-term impact of this novel treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [<sup>18</sup>F]DCFPyL (PSMA) imaging for standardized reporting.
Johnsson K, Brynolfsson J, Sahlstedt H, Nickols NG, et al · · 2022 · cited 42× · PMID 34463809 · DOI 10.1007/s00259-021-05497-8
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
Sandhu S, Guo C, Hofman MS. · · 2021 · cited 34× · PMID 34385339 · DOI 10.2967/jnumed.120.243295
<sup>89</sup>Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
Privé BM, Derks YHW, Rosar F, Franssen GM, et al · · 2022 · cited 30× · PMID 34932154 · DOI 10.1007/s00259-021-05661-0
More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.
Hyväkkä A, Virtanen V, Kemppainen J, Grönroos TJ, et al · · 2021 · cited 22× · PMID 34067046 · DOI 10.3390/cancers13092244
Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives.
Seifert KE, Seifert R, Kessel K, Roll W, et al · · 2021 · cited 17× · PMID 34359614 · DOI 10.3390/cancers13153715
Impact of PSMA PET on Prostate Cancer Management.
Weiner AB, Agrawal R, Valle LF, Sonni I, et al · · 2024 · cited 15× · PMID 38270802 · DOI 10.1007/s11864-024-01181-9
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study.
Banda A, Privé BM, Allach Y, Uijen MJM, et al · · 2022 · cited 14× · PMID 36612293 · DOI 10.3390/cancers15010297
PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues.
Hoshi S, Yaginuma K, Meguro S, Onagi A, et al · · 2023 · cited 10× · PMID 37623010 · DOI 10.3390/curroncol30080529

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Rabin Medical Center trials

Trials by the same sponsor.

NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04297410 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
Last refreshed: 5 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04297410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing